Retinset

Executive Summary

Retinset is a clinical-stage biotechnology company based in Barcelona, Spain, focused on developing non-invasive ophthalmic therapeutics for neurovascular retinal diseases. Its lead program, BSL01, is a first-in-class eye drop formulation designed to prevent and treat early-stage diabetic retinopathy, a leading cause of vision loss. By offering a non-invasive alternative to current intravitreal injections, BSL01 has the potential to improve patient compliance and reduce treatment burden. The company is currently in Phase 1 clinical development, targeting a large and growing market as diabetic retinopathy affects millions worldwide. Retinset's innovative approach and early-stage progress position it as an attractive candidate for future partnerships or investment, though it faces typical preclinical and clinical risks common to early biotech ventures.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 Safety and Tolerability Data Readout70% success
• TBDStrategic Partnership or Licensing Deal40% success
• Q4 2026Series A or Bridge Financing Round50% success